Irene Urbino, MD, Città della Salute e della Scienza di Torino, Turin, Italy discusses the efficacy of blinatumomab given as consolidation in adults with B-cell precursor acute lymphoblastic leukemia (B-ALL). Dr Urbino describes how, in this real-world evidence study, patients with B-ALL were divided into three subgroups - those in first complete remission (CR1), those in second CR after chemotherapy-base salvage therapy (CR2), and those in overt relapse (R/R). The results of the study highlight that blinatumomab should preferably be used in consolidation rather than as salvage therapy in patients with B-ALL in first relapse. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
